News Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Real-time Estimate Cboe BZX Other stock markets 11:41:41 2024-04-16 am EDT			5-day change	1st Jan Change
38.57 ^USD	-0.39%		-3.91%	+4.33%

Mar. 13	Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	MT
Mar. 13	Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Halozyme Therapeutics Insider Sold Shares Worth $839,100, According to a Recent SEC Filing	Mar. 13	MT
Transcript : Halozyme Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 10:45 AM	Mar. 13
Transcript : Halozyme Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM	Mar. 05
Halozyme to Participate in Upcoming Investor Conferences	Feb. 27	PR
HC Wainwright Adjusts Halozyme Therapeutics Price Target to $50 From $48, Maintains Buy Rating	Feb. 21	MT
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21	MT
Transcript : Halozyme Therapeutics, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
Halozyme Therapeutics: Q4 Earnings Snapshot	Feb. 20	AQ
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	Feb. 20	CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	Feb. 20	MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	Feb. 20	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	Feb. 20	MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	Feb. 20	MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20	CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20	CI
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS	Feb. 20	PR
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20	CI
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results	Feb. 08	PR
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31	CI
Halozyme Announces Takeda Received European Commission Approval for HYQVIA Co-formulated with ENHANZE as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Summary

Filters